Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus MAXIPIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus MAXIPIME.
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER vs MAXIPIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3 in Gram-negative bacteria, leading to cell lysis and death.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has enhanced activity against Gram-negative bacteria due to rapid penetration through the outer membrane and low affinity for β-lactamases.
1-2 g IV every 8-12 hours for moderate to severe infections; for febrile neutropenia, 2 g IV every 8 hours.
1-2 g IV every 8-12 hours for most indications; maximum 2 g every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life ≈2.0–2.3 hours in healthy adults; prolonged to 13–26 hours in severe renal impairment (CrCl <10 mL/min); relevant for dosing interval adjustment.
Terminal elimination half-life is approximately 2-2.5 hours in adults with normal renal function; extends to 8-12 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 20-24 hours in severe impairment (CrCl < 30 mL/min).
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Primarily renal (approximately 80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (< 1%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic